Niki BioSolutions, Inc. SEC Filings

Niki BioSolutions, Inc. director Kira S. Sheinerman reports beneficial ownership of 1,515,293 shares of Niki common stock, representing approximately 51.56% of the 2,938,625 shares outstanding as of the merger closing.

These shares were issued as non-cash merger consideration in exchange for DiamiR Biosciences Corp. stock under a July 14, 2025 merger agreement, which closed on July 20, 2026 when Aptorum Group Limited domesticated to Delaware and was renamed Niki BioSolutions, Inc. Under a Stockholders Agreement, Sheinerman may designate two board nominees while owning at least 36% of the common stock, and one nominee while owning at least 25%. While she holds at least 25%, certain significant corporate actions require her prior written consent, and transfers of covered shares are generally restricted for six months after the agreement’s effective date. Niki common stock trades on the Nasdaq Capital Market under the ticker symbol \"NIKI\".

Niki BioSolutions, Inc. director Laura A. Philips filed an initial ownership report on Form 3. On 2026-07-20 she reported direct beneficial ownership of 6,024 shares of Common Stock of Niki BioSolutions. The filing lists this holding as a baseline position and does not report any buy or sell transactions.

Niki BioSolutions, Inc. director and more-than-10% owner Sheinerman Kira reported beneficial ownership of 1,515,293 shares of Common Stock. Of these, 1,515,016 shares are held directly and 277 shares are held in a joint brokerage account with shared voting and dispositive power.

On July 20, 2026, Aptorum Group Limited completed its all-stock merger with DiamiR Biosciences Corp., after a domestication from Cayman to Delaware, and was renamed Niki BioSolutions, Inc.. Niki’s common stock now trades on the Nasdaq Capital Market under the symbol NIKI with CUSIP 653942 102.

As part of the transaction, each Aptorum Class A ordinary share converted 1-for-1 into Niki common stock, and each Class B ordinary share converted into one Niki common share plus one share of non-voting, non-convertible Series A Preferred Stock. Aptorum holders received 814,375 Niki common shares and 179,693 Series A Preferred shares, while DiamiR stockholders received 1,979,216 Niki common shares based on a defined Conversion Ratio. Immediately before closing, Aptorum implemented a 10-for-1 reverse share split, reducing outstanding Class A shares from 6,346,823 to 634,682 and Class B from 1,796,934 to 179,693. Niki adopted new Delaware charter documents, designated 1,810,000 preferred shares as Series A, and approved a 2026 Equity Incentive Plan reserving 4,500,000 common shares plus an annual evergreen increase.

Aptorum Group Limited is extending its planned merger with DiamiR Biosciences by pushing the merger Termination Date and related agreements out to July 31, 2026. The companies originally signed an Agreement and Plan of Merger on July 14, 2025, along with a Management Services Agreement and an intellectual property license agreement.

Those agreements were initially scheduled to end on December 31, 2025, but a new amendment to the Management Services Agreement formalizes the extension while the parties continue working to satisfy closing conditions. Aptorum has also filed a registration statement on Form S-4, which was declared effective on May 13, 2026, to support the proposed combination.

Aptorum Group Limited reports that its shareholders approved a proposed all-stock merger with DiamiR Biosciences Corp. at an extraordinary general meeting. Shareholders representing 2,848,680 Class A and Class B shares, or 97.15% of the voting power entitled to vote, were present by proxy, and all proposals passed with overwhelming support. DiamiR’s shareholders also approved the merger on the same date. The merger will make DiamiR a wholly owned subsidiary of Aptorum, but completion still depends on satisfying or waiving remaining customary closing conditions, and the companies currently expect the transaction to close before fiscal 2027.

Aptorum Group Limited is registering up to 2,060,000 Class A Ordinary Shares issuable upon the exercise of certain warrants for resale by the named Selling Securityholders.

The registration covers (i) up to 2,000,000 Investor Warrant Shares exercisable at $2.00 per share (October 2025 Warrants) and (ii) 60,000 Placement Agent Warrant Shares exercisable at $2.50 per share. The Company states it will not receive proceeds from Selling Securityholders’ resale transactions but will receive cash exercise proceeds when warrants are exercised for cash. The prospectus warns that large resales could pressure the market; the last reported sale price was $1.09 per share as of June 3, 2026.

Aptorum Group Limited filed a post-effective amendment to register up to 2,060,000 Class A Ordinary Shares issuable upon exercise of warrants (the “2025 Warrants”), including 2,000,000 Investor Warrants at an original exercise price of $2.00 and 60,000 Placement Agent Warrants at $2.50. The prospectus registers resale by the selling securityholders; the Company will not receive proceeds from resale but will receive cash exercise proceeds when warrants are exercised for cash. The filing discloses risks tied to the Company’s Hong Kong operations, PRC regulatory uncertainty including the CSRC Trial Measures and HFCAA/PCAOB inspection risks, and summarizes the pending DiamiR merger and related governance, consideration and conditionality.